当前位置： SCI文献检索 > Clinical Lung Cancer期刊下所有文献 > Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.

Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.

Abstract：

:Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of neoadjuvant chemotherapy with platinum doublets and most recently novel targeted agents, such as dasatinib. Intrapleural strategies have included injecting chemotherapy, chemotherapy with hyper thermic per fusion, gene therapy, and immunotherapy. The following review discusses the latest results in neoadjuvant and intrapleural therapies in malignant pleural mesothelioma.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Tsao AS,Mehran R,Roth JA

doi

10.3816/CLC.2009.n.005

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

36-41

issue

1

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(11)70079-1

journal_volume

10

pub_type

杂志文章,评审

相关文献

Clinical Lung Cancer文献大全
  • Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.

    abstract：BACKGROUND:Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, clinical characteristics, and survival outcome in these patien...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2019.07.003

    authors： Cheng H,Hosgood HD,Deng L,Ye K,Su C,Sharma J,Yang Y,Halmos B,Perez-Soler R

    更新日期：2020-03-01 00:00:00

  • Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

    abstract：BACKGROUND:The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.02.002

    authors： Lin C,Chen X,Li M,Liu J,Qi X,Yang W,Zhang H,Cai Z,Dai Y,Ouyang X

    更新日期：2015-09-01 00:00:00

  • Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion.

    abstract：BACKGROUND:Malignant pleural effusion (MPE) has a profound impact on quality of life and survival in patients with lung cancer. Identification of the factors within the tumor and its environment that mediate MPE is still lacking. PATIENTS AND METHODS:Intratumoral microvessel density (MVD), endothelial cell and pericyt...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.06.007

    authors： Damianovich M,Hout Siloni G,Barshack I,Simansky DA,Kidron D,Dar E,Avivi C,Onn A

    更新日期：2013-11-01 00:00:00

  • Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.

    abstract：:The identification of tumor biomarkers provides information on the prognosis and guides the implementation of appropriate treatment in patients with many different cancer types. In non-small cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification have already been used in the clinic. Howev...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2014.06.005

    authors： Slavik T,Asselah F,Fakhruddin N,El Khodary A,Torjman F,Anis E,Quinn M,Khankan A,Kerr KM

    更新日期：2014-11-01 00:00:00

  • A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.

    abstract：BACKGROUND:The aim of this trial was to determine feasibility of incorporating bevacizumab (B) into concurrent chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Patients with unresectable stage III NSCLC, performance status of 0 to 1, and adequate organ function were...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2014.12.014

    authors： Wozniak AJ,Moon J,Thomas CR Jr,Kelly K,Mack PC,Gaspar LE,Raben D,Fitzgerald TJ,Pandya KJ,Gandara DR

    更新日期：2015-09-01 00:00:00

  • Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.

    abstract：:Small-cell lung cancer (SCLC) is distinguished from non-small-cell lung cancer by its rapid growth and more frequent metastases. Although patients with SCLC are highly responsive to chemotherapy and radiation therapy, long-term prognosis remains poor, with relapse and disease recurrence occurring in almost all cases. ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2016.07.004

    authors： Chae YK,Pan A,Davis AA,Mohindra N,Matsangou M,Villaflor V,Giles F

    更新日期：2017-03-01 00:00:00

  • Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.

    abstract：:There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival ad...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2011.06.002

    authors： Carbone DP,Felip E

    更新日期：2011-09-01 00:00:00

  • Expression levels of protein kinase C-alpha in non-small-cell lung cancer.

    abstract：:Current treatments of non-small-cell lung cancer (NSCLC) are inadequate and new therapies are being developed that target specific cellular signaling proteins associated with tumor growth. One potential target is protein kinase C (PKC)-alpha, a signaling molecule with an important role in cell regulation and prolifera...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2004.n.032

    authors： Lahn M,Su C,Li S,Chedid M,Hanna KR,Graff JR,Sandusky GE,Ma D,Niyikiza C,Sundell KL,John WJ,Giordano TJ,Beer DG,Paterson BM,Su EW,Bumol TF

    更新日期：2004-11-01 00:00:00

  • Emerging antiangiogenic agents in lung cancer.

    abstract：:The success of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in numerous tumor types including non-small-cell lung cancer (NSCLC) has spurred the development of additional novel antiangiogenic agents with distinct mechanisms of action. These include the small-molecule receptor tyrosine kinase...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2006.n.010

    authors： Lee D,Heymach JV

    更新日期：2006-03-01 00:00:00

  • External Validation of the New International Association for the Study of Lung Cancer Tumor, Node, and Metastasis 8th Edition Staging System and Updated T Descriptors in Determining Prognosis for Patients With Non-Small Cell Lung Cancer Patients With N3 D

    abstract：OBJECTIVE:The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS:Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-squ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.05.009

    authors： Shin JY,Yoon JK,Marwaha G

    更新日期：2017-11-01 00:00:00

  • Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.

    abstract：BACKGROUND:The optimal treatment of locally advanced non-small-cell lung cancer (NSCLC) remains controversial. We hypothesized that using a trimodality approach in selected patients with stage IIIA/IIIB disease would be both feasible and efficacious with reasonable toxicity. PATIENTS/METHODS:We enrolled 13 patients wi...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.06.003

    authors： Das M,Donington JS,Murphy J,Kozak M,Eclov N,Whyte RI,Hoang CD,Zhou L,Le QT,Loo BW,Wakelee H

    更新日期：2011-09-01 00:00:00

  • Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.

    abstract：BACKGROUND:The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. PATIENTS AND METHODS:We r...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.01.013

    authors： Handa Y,Tsutani Y,Shiroma N,Kai Y,Mimae T,Miyata Y,Takeshima Y,Arihiro K,Okada M

    更新日期：2020-07-01 00:00:00

  • RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

    abstract：:Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The associ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2018.06.005

    authors： Imbimbo M,Vitali M,Fabbri A,Ottaviano M,Pasello G,Petrini I,Palmieri G,Berardi R,Zucali P,Ganzinelli M,Marabese M,Broggini M,Marino M,Trama A,Rulli E,Hollander L,Pruneri G,Torri V,Garassino MC

    更新日期：2018-09-01 00:00:00

  • Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer.

    abstract：INTRODUCTION/BACKGROUND:The aim of this study was to identify imaging-based predictors of progression in patients treated with SABR for stage I NSCLC. PATIENTS AND METHODS:Between March 2003 and December 2012, 117 patients with stage I NSCLC meeting our study criteria were treated with SABR at Stanford University. Med...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.011

    authors： Shultz DB,Trakul N,Abelson JA,Murphy JD,Maxim PG,Le QT,Loo BW Jr,Diehn M

    更新日期：2014-07-01 00:00:00

  • Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.

    abstract：UNLABELLED:Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. M...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.05.001

    authors： Carpentier O,Selvaggi L,Jégu J,Purohit A,Prim N,Velten M,Quoix E

    更新日期：2015-11-01 00:00:00

  • Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

    abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.007

    authors： Russell K,Healy B,Pantarotto J,Laurie SA,MacRae R,Sabri E,Wheatley-Price P

    更新日期：2014-05-01 00:00:00

  • A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

    abstract：:Docetaxel has demonstrated activity as a radiosensitizer in numerous preclinical studies, probably due to its role as a cell cycle synchronizer for the G2/M radiosensitive phase of the cell cycle. We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of docetaxel...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2000.s.006

    authors： Choy H,DeVore RF,Hande KR,Porter LL,Rosenblatt PA,Slovis B,Laporte K,Shyr Y,Johnson DH

    更新日期：2000-04-01 00:00:00

  • Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.

    abstract：BACKGROUND:Limited data is available on comorbidity assessment in patients with lung cancer. The present prospective study assessed the prevalence and association of the Charlson comorbidity index (CCI) and simplified comorbidity score (SCS) with clinical outcomes in patients with newly diagnosed lung cancer undergoing...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.10.002

    authors： Singh N,Singh PS,Aggarwal AN,Behera D

    更新日期：2016-05-01 00:00:00

  • Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.

    abstract：PURPOSE:We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of topotecan when administered weekly to patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS:Twelve patients with s...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2010.n.035

    authors： Masuda N,Matsui K,Negoro S,Takeda K,Kudoh S,Nakagawa K,Mukaiyama A,Arase H,Yoshida P,Ijima T,Takada M,Fukuoka M

    更新日期：2010-07-01 00:00:00

  • Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.

    abstract：:This study was designed as a multicenter, randomized, double-blind, placebo-controlled trial. Patients were randomized by center to placebo (16 patients, 31%), oral bexarotene 300 mg/m2/day (21 patients, 40%), or oral bexarotene 600 mg/m2/day (15 patients, 29%) following demonstration of stable or responsive disease a...

    journal_title：Clinical lung cancer

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.3816/clc.2001.n.005

    authors： Rizvi N,Hawkins MJ,Eisenberg PD,Yocum RC,Reich SD,Ligand L1069-20 Working Group.

    更新日期：2001-02-01 00:00:00

  • Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.

    abstract：BACKGROUND:In the present study we aimed to investigate whether the predominance of the lepidic component in tumors was associated with the outcome of postoperative adjuvant chemotherapy for stage I lung adenocarcinoma. PATIENTS AND METHODS:Charts for patients with pathological stage I lung adenocarcinoma were retrosp...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.11.015

    authors： Sasada S,Miyata Y,Mimae T,Tsutani Y,Mimura T,Okada M

    更新日期：2016-09-01 00:00:00

  • Current development of adjuvant treatment of non-small-cell lung cancer.

    abstract：:Although radical surgery remains the mainstay therapeutic modality for early-stage non-small-cell lung cancer (NSCLC), long-term survival of patients with completely resected NSCLC tumors remains suboptimal. Globally, the 5-year survival rate of patients who undergo complete surgical resection is in the range of 40%-5...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/clc.2004.s.016

    authors： Scagliotti GV,Novello S

    更新日期：2004-12-01 00:00:00

  • Disparities in the Management of Patients With Stage I Small Cell Lung Carcinoma (SCLC): A Surveillance, Epidemiology and End Results (SEER) Analysis.

    abstract：INTRODUCTION:Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to receive surgery. METHODS:The Surveillance, Epidemiology an...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.03.003

    authors： Ahmed Z,Kujtan L,Kennedy KF,Davis JR,Subramanian J

    更新日期：2017-09-01 00:00:00

  • Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomography.

    abstract：INTRODUCTION:To prospectively evaluate the frequency and spectrum of incidental findings (IF) in a 5-year lung cancer screening program with low-dose spiral computed tomography (CT) and to estimate the additional costs of their imaging workup incurred from subsequent radiologic follow-up evaluation. MATERIALS AND METH...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2012.05.005

    authors： Priola AM,Priola SM,Giaj-Levra M,Basso E,Veltri A,Fava C,Cardinale L

    更新日期：2013-03-01 00:00:00

  • Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodes.

    abstract：BACKGROUND:Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS:We reviewed 187 patients with NSCLC pN1-N2 w...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.04.012

    authors： Ito M,Yamashita Y,Tsutani Y,Misumi K,Harada H,Miyata Y,Okada M

    更新日期：2013-11-01 00:00:00

  • Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

    abstract：BACKGROUND:Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Uni...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2019.02.006

    authors： Cortellini A,Chiari R,Ricciuti B,Metro G,Perrone F,Tiseo M,Bersanelli M,Bordi P,Santini D,Giusti R,Grassadonia A,Di Marino P,Tinari N,De Tursi M,Zoratto F,Veltri E,Malorgio F,Garufi C,Russano M,Anesi C,Zeppola T,

    更新日期：2019-07-01 00:00:00

  • Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

    abstract：:Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We re...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.010

    authors： Grenader T,Gipps M,Goldberg A

    更新日期：2008-01-01 00:00:00

  • Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.

    abstract：PURPOSE:This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received gemcitabine 3000 mg/m(2) intravenously over 30 minutes and paclitaxel 15...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2007.n.010

    authors： Wozniak AJ,Belzer K,Heilbrun LK,Kucuk O,Gadgeel S,Kalemkerian GP,Venkatramanamoorthy R,Kraut MJ

    更新日期：2007-03-01 00:00:00

  • The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.

    abstract：:After decades of platinum-based chemotherapy for advanced small-cell lung cancer, there has finally been a therapeutic advance. The combination of a platinum chemotherapy, etoposide, and an immune checkpoint inhibitor has yielded overall survival benefits in two successive phase 3 trials. Unfortunately, these trials o...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.04.006

    authors： Friedlaender A,Liu SV,Passaro A,Metro G,Banna G,Addeo A

    更新日期：2020-11-01 00:00:00

  • PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III no

    abstract：:This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.3816/CLC.2009.n.027

    authors： Vokes EE,Senan S,Treat JA,Iscoe NA

    更新日期：2009-05-01 00:00:00